Search

Displaying results 2461 - 2470 of 10000 in total
  1. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. … Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin.

  2. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]

    Products: ALDACTONE A, SPIRONOLACTON AL 50
  3. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.

  4. Drug

    Benzthiazide

    go.drugbank.com/drugs/DB00562
    Approved

    They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. … Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

  5. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment … remain in clinical development.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults.

  7. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.

  8. Drug

    Prasterone

    go.drugbank.com/drugs/DB01708
    ApprovedInvestigationalNutraceutical

    In Canada, a prescription is required to buy DHEA. … Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary.

    Synonyms: 3β-hydroxyandrost-5-en-17-one, 3beta-hydroxyandrost-5-en-17-one
  9. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. … In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.

  10. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Anisindione is a synthetic anticoagulant and an indanedione derivative. … II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver.